Keywords: Lundbeck, Lu AE58054, Alzheimer's disease

Alzheimer's drug candidate Lu AE58054 meets primary endpoint, says Lundbeck

Article | 29 May 2012

Print This

Danish CNS drug specialist Lundbeck (LUND: DC) announced this morning that its investigational compound Lu AE58054 has met its primary ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in